Berger Anna
About Berger Anna
Berger Anna is the Senior Medical Manager Hematology at Bristol Myers Squibb in München, with over a decade of experience in various medical advisory roles, specializing in hematology and oncology.
Current Role at Bristol Myers Squibb
Since October 2020, Berger Anna has been serving as the Senior Medical Manager Hematology at Bristol Myers Squibb in München, Bayern, Deutschland. In this role, she is responsible for overseeing medical affairs related to hematology, leveraging her extensive experience in the field. Her responsibilities include providing strategic medical guidance and supporting the development of medical strategies and initiatives.
Previous Roles in Hematology at Bristol Myers Squibb
Before assuming her current role, Berger Anna worked as a Medical Advisor Hematology at Bristol Myers Squibb from 2018 to 2020. During this time, she focused primarily on Multiple Myeloma and Chronic Myeloid Leukemia (CML). In these roles, she contributed to various medical advisory projects, drawing from her deep expertise in hematology.
Experience in Oncology at Bristol Myers Squibb
From 2014 to 2018, Berger Anna served as a Medical Advisor Oncology at Bristol Myers Squibb. Her work involved managing medical affairs for critical oncology areas such as Melanoma, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC). This role helped her build a robust foundation in oncology before she transitioned to hematology.
Background in Medical Advisory Roles
Berger Anna began her journey at Bristol Myers Squibb as an MSM from 2011 to 2014. She then took on interim roles, including Interim Medical Advisor from 2013 to 2014, before becoming a full-fledged Medical Advisor in oncology and hematology. Her career path at Bristol Myers Squibb showcases over a decade of dedicated service and experience in medical advisory capacities.
Expertise in Hematology and Oncology
With a career spanning over ten years at Bristol Myers Squibb, Berger Anna brings a wealth of knowledge in both hematology and oncology. She has managed medical affairs in crucial therapeutic areas like Multiple Myeloma, Chronic Myeloid Leukemia (CML), Melanoma, and lung cancers (NSCLC and SCLC). Her transition from oncology advisory roles to hematology management underscores her versatile expertise and dedication to advancing medical science.